A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients

• Status: Completed
• Trial end date: 2020-09-14
• Target enrollment: 0
• Participant gender: All

Summary

Randomized, double-blind, placebo-controlled study on the effects of MIN-102 on Biochemical, Imaging, neurophysiological, and clinical markers in patients with Friedreich's Ataxia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Minoryx Therapeutics, S.L.

Criteria

Inclusion Criteria:

• Male and female subjects aged ≥12 and ≤60 years, inclusive, with a genetically confirmed diagnose of Friedreich's Ataxia.

• Be able to walk > 10 meters with support (two special sticks, stroller or accompanying person).

• Total Score on the Scale for the Assessment and Rating of Ataxia (SARA) of < 25.

Exclusion Criteria:

• Age of onset of disease ≥25 years.

• Higher degree of cardiomyopathy assessed by echocardigram.

• Diabetes